Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Curaleaf Holdings, Inc.

OTC: CURLF · Life Sciences · 14 alerts · CIK 1756770

Share price
$8.10Close, Nov 16
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Curaleaf Holdings, Inc. filings on SEC EDGAR ↗

3:01 PM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings announced it has received all required competition law clearances from regulators in Germany and Canada for its proposed acquisition of Aurora Cannabis Inc. The company's enhanced premium bid to acquire all outstanding shares of Aurora remains open until December 4, 2026, as it competes against a rival proposal from Organigram.

Counterparty
Aurora Cannabis Inc.
12:51 PM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings issued a statement reaffirming its outstanding premium bid to acquire all common shares of Aurora Cannabis, despite Aurora announcing an alternative transaction with Organigram Global Inc. Curaleaf argues its offer provides superior value and synergies compared to the Organigram proposal and criticized the Aurora board for refusing to engage directly or grant due diligence access.

Counterparty
Aurora Cannabis Inc.
5:27 PM ET 10-Q
Financial Results

Curaleaf Holdings Q3 2026 Results: Net Loss of $32.7M, Loss Narrows

Curaleaf Holdings, Inc. filed its 10-Q for the period ending September 30, 2026, reporting 233,672,570 Subordinate Voting Shares outstanding. The filing highlights significant risks including the federal illegality of cannabis in the U.S., potential regulatory changes, and the company's proposed redomicile transaction.

Key figure
Net loss $32.7M
4:03 PM ET 8-K
Financial Results

Curaleaf Holdings Financial Results

Curaleaf Holdings reported record third-quarter 2026 revenue of $352.7 million, a 10.9% year-over-year increase driven by strong domestic and international growth. Despite the revenue record, the company reported a net loss from continuing operations of $37.4 million for the quarter, while maintaining an adjusted EBITDA margin of 22%.

Term
Q3 2026

“We are building the global leader in cannabis, and our third-quarter results provide further evidence that our strategy is delivering. Solid execution across the business is driving growth, strengthening our competitive position, and advancing our Built for Growth plan.”

Boris Jordan, Chairman and CEO

“These results reflect the disciplined execution of our entire team and reinforce the strength of our global platform. We are translating operational improvements into stronger financial performance, building momentum across the business, and positioning Curaleaf for sustained growth and greater cash generation.”

Boris Jordan, Chairman and CEO
6:01 AM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Boone Town Provisions

Curaleaf Holdings has acquired an equity stake and certain operating rights in Boone Town Provisions, a high-performing cannabis dispensary in Boonton, New Jersey. The acquisition expands Curaleaf's retail footprint to four dispensaries in New Jersey and 191 nationwide. The transaction is expected to be immediately accretive to the company's New Jersey operations.

Counterparty
Boone Town Provisions

“Boone Town Provisions is one of the top-performing dispensaries in New Jersey. We have acquired our interest in the dispensary at an attractive valuation that aligns with our disciplined approach to capital allocation. The acquisition strengthens our position in New Jersey, allows us to increase our vertical position, adds a proven, high-performing location to our retail footprint, and expands access to our brands for more customers in the state.”

Boris Jordan, Chairman and CEO of Curaleaf
3:00 PM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings issued a status update regarding its hostile takeover bid for Aurora Cannabis, responding to a ruling by the Alberta Securities Commission. Curaleaf is advocating for its enhanced offer, which it values at approximately $5.00 per share (an 86% premium), while criticizing Aurora's board for dilutive share issuances and for excluding Curaleaf from the strategic review process.

Counterparty
Aurora Cannabis Inc.

“Aurora would like shareholders to believe the ASC's ruling changes the fundamental debate. It does not. The questions confronting Aurora shareholders remain the same today as they were yesterday: why did Aurora issue shares under an ATM for less than the original offer price after Curaleaf indicated a bid was coming, why is a now 86% premium offer being dismissed as inadequate and a discounted offer, why is Curaleaf continuing to be excluded from customary diligence when others aren't, and why is the Board asking shareholders to reject a proposal before allowing a fully informed process to play out?”

Boris Jordan, Chairman of the Board and Chief Executive Officer of Curaleaf
4:23 PM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings, Inc. responded to Aurora Cannabis Inc.'s rejection of its enhanced acquisition proposal, challenging the Aurora Board's refusal to grant due diligence access. Curaleaf noted its offer represents an 86% premium to Aurora's unaffected 30-day VWAP and criticized Aurora for providing diligence access to other unnamed parties while obstructing Curaleaf's binding offer.

Counterparty
Aurora Cannabis Inc.
1:47 PM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings, Inc. has filed a formal Notice of Variation to increase its offer to acquire all outstanding shares of Aurora Cannabis Inc. The enhanced offer provides total implied consideration of US$5.00 per share, consisting of 0.4013 Curaleaf shares and US$1.00 in cash, representing an 86% premium to Aurora's unaffected share price.

Counterparty
Aurora Cannabis Inc.
8:38 AM ET 8-K
M&A Deal

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings, Inc. has filed a Notice of Variation to its existing tender offer to acquire all outstanding shares of Aurora Cannabis Inc. The amended offer increases the consideration to US$1.00 in cash plus 0.4013 Curaleaf subordinate voting shares per Aurora share and extends the expiry date to December 4, 2026.

Counterparty
Aurora Cannabis Inc.
6:01 AM ET 8-K
Stock Plan Amendment

Curaleaf Holdings Stock Plan Amendment

Curaleaf Holdings approved a compensation package for Chairman and CEO Boris Jordan, including a one-time grant of 1,344,275 restricted stock units with a grant date fair value of approximately $15.45 million. The board also increased his 2027 short-term incentive target to 200% of base salary and established a $1 million discretionary target bonus for strategic objectives.

5:28 PM ET 8-K
Other 8-K Filing

Curaleaf Holdings Other 8-K Filing

Curaleaf Holdings announced its addition to the FTSE Canada All Cap Index, effective September 18, 2026. This marks the company's second major Canadian benchmark inclusion following its 2025 addition to the S&P/TSX Composite Index, which management expects will increase liquidity and institutional investor exposure.

Counterparty
FTSE Russell

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.